輝瑞洽購法國製藥公司Cellectis

Cellectis, the French biotech company, is in talks about its potential sale with Pfizer of the US believed to be among the buyers.

法國生物科技公司Cellectis正就可能的出售事宜與美國的輝瑞(Pfizer)展開談判。據信輝瑞是潛在買家之一。

Two people familiar with the situation said Cellectis was in negotiations over a deal but warned that no outcome was certain. One person said Pfizer had informally approached the company about a deal that could value the target at as much as 1.5bn.

兩位知情人士表示，Cellectis正就收購協議進行談判，但他們警告稱結果尚不確定。其中一人表示，輝瑞已非正式地接洽該公司、提出了一份收購協議，對該公司的估值可能高達15億歐元。

The US drug company already owns 9.47 per cent of Cellectis after the pair forged a partnership to develop cancer drugs.

輝瑞此前曾與Cellectis建立合作關係、共同開發抗癌藥，如今已擁有後者9.47%的股份。

It is unclear if other parties were also in the sale talks with Cellectis. Pfizer declined to comment and Cellectis had no immediate comment.

目前尚不清楚是否有其他潛在買家也在與Cellectis談判收購事宜。目前輝瑞拒絕置評，Cellectis沒有馬上發表評論。

An acquisition of Cellectis would strengthen Pfizer’s push to become a serious player in a new category of cancer drugs called immuno-oncology.

輝瑞正努力成爲作爲抗癌藥物新領域——免疫-腫瘤學領域——的舉足輕重的公司。收購Cellectis將強化輝瑞在這方面的努力。

The French company, which raised $228m in a Nasdaq initial public offering in March, specialises in a type of treatment known as Car-T therapy seen as one of the hottest areas of drug development.

今年3月，Cellectis在納斯達克(Nasdaq)進行了首次公開發行(IPO)，募資2.28億美元。該公司專門從事一種被稱爲“嵌合抗原受體T細胞療法”(CAR-T)的治療方法，這是當今最熱門的藥物開發領域之一。